Anti-Pembrolizumab (Keytruda®) (Human) ELISA Kit

Product Overview

A Sandwich ELISA kit for the qualitative determination of antibody against Pembrolizumab in human serum or plasma.

Pembrolizumab (Keytruda®) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. 96Trace’s BioSimTM anti-Pembrolizumab ELISA kit is designed to detect antibody against Pembrolizumab with high specificity and sensitivity in biological matrices.

Assay Information

Applications

This ELISA kit is used for Qualitative determination of antibody against Pembrolizumab (Keytruda) in serum and plasma

Features & Benefits

• Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Pembrolizumab (Keytruda) in human serum and plasma.
• Cross Reactivity: Pembrolizumab (Keytruda®) infusion camouflages/masks the presence of antibody to Pembrolizumab (ATP) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATP. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Pembrolizumab.

Storage & Shipping

Product Details